

Identifying Patients for Pharmacogenomic Testing

PREVIOUS MEDICATION FAILURE



Patient Age: 22



Genetic Variability Profile

SLC6A4 (S/S), highly inducible CYP1A2 variant (non-smoker)



Primary Psychiatric Diagnosis

Major Depressive Disorder with Comorbid Anxiety

Target Psychiatric Symptoms

Depression, sleep disturbances, lack of motivation, anhedonia, fatigue, hopelessness, feelings of guilt, excessive worry

Medication History

Previous: sertraline 100 mg, fluvoxamine 50 mg

Current: fluoxetine 20 mg

Patient Reported Progress

Patient reports some days feel better than others, but is still suffering from feelings of depression, anhedonia, fatigue, and not feeling like herself.

Treatment Changes Considered Prior to the GeneSight Test

Increase dose of current medication, fluoxetine, from 20 mg to 40 mg



This case study is a simplified, illustrative example of how insights from the GeneSight test can be used to help inform treatment. This is not a real GeneSight patient case. These genetic insights should be used within the context of a comprehensive medical assessment.

How Genetic Insights Helped Inform Treatment Decisions

Insights Revealed in the GeneSight® Report

- Fluoxetine was listed in the yellow category (Moderate Gene-Drug Interaction) of the patient's report.
- Clinical Consideration 4 added that "Genotype may impact drug mechanism of action and result in moderately reduced efficacy."
- Clinician deduced that increasing the dose was unlikely to increase efficacy, as genotype may impact drug mechanism of action, per Clinical Consideration 4.
- Considered selecting a medication that is not expected to be affected by this genetic variation.

Treatment Changes Made After the GeneSight Test

Discontinued fluoxetine and initiated duloxetine 30 mg, listed in the patient's green category (Use as Directed) for the "non-smokers" section of results

Patient Outcome

By supplementing their comprehensive medical assessment with insights from the GeneSight test, the clinician was able to create a personalized medication plan that addressed the patient's target symptoms.

Patient displayed improved quality of sleep, increased motivation, less feelings of excessive guilt, and ability to re-engage in recreational hobbies.